

## Index

### a

- absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) 39, 283
- Accelrys FCFP4 fingerprint 110
- activity Cliff-forming scaffolds 71, 72
  - activity Cliff concept 71
  - multitarget Cliff-forming scaffolds 71–73
- AllChem 94
- N-alpha-(2-naphthyl-sulphonyl-glycyl)-DL-pamidinophenylalanyl-piperidine (NAPAP) ligand 238, 239
- amino acid
  - interaction types 223
  - pharmacophoric properties 221
  - residues, responsible for binding of 261
  - sequence 172, 260
  - specific binding 223
- AstraZeneca 17, 87
  - virtual library 95
- acyclic fragments 233
- AZ-VL system 97

### b

- bacterial neuraminidase, X-ray crystal structure 241
- BCI fingerprint 110
- benzimidazole scaffold 3
- BI CLAIM system 97
- binding affinity 3, 48, 221, 222, 264, 265, 268, 269, 273
- binding conformation, superimposition of 287
- BindingDB 64
- bioisostere encoding 144
- bioisosteric replacements 247, 259
- BIOSTER database 144
- bis(trifluoromethyl)phenyl rings 266
- BROOD system 179
  - bioisosteric similarity methods 180

### c

- calcium-dependent NOS activity 290
- calmodulin (CaM) 284
- Cambridge Structural Database (CSD) 271
- CAS. *see* Chemical Abstracts Service (CAS)
- CAS (Chemical Abstracts Service) registry 43, 46
  - nonredundant library 46
- CATS. *see* chemically advanced template search (CATS)
- CATS 2D autocorrelation function 111
- CATS fingerprints 108, 111, 114
- cavity-independent fingerprints (APIF) 222
- cerebral palsy, prevention 289
- CG. *see* chemical graph (CG)
- ChEMBL database 44, 49, 52, 53, 55, 62, 97
- ChEMBL data set 111
- Chemical Abstracts Service (CAS) 16, 43
- chemical clichés 44
- chemical graph (CG) 131, 133
  - paracetamol molecular structure 132
- chemically advanced template search (CATS) 119–122
  - CATS2 atom types 121
  - descriptor
    - generation 122
    - median BEDROC performance 125
    - fuzzy molecular representations 120
    - modify ATS descriptor 120
- chemical patent 15, 17, 28, 34, 36
- chemical space 83, 84
  - comprehensive enumeration 85
  - BOOMSLANG algorithm 88
  - fragments 85, 86
  - Kohonen map 86
  - reagents 87, 88
  - ring systems 86, 87
  - SMIRKS manipulation 87

- VEHICLE 86
  - iterative stochastic search 85
  - perspective 99
  - chemoinformatics 107
  - claimed intellectual property 17
  - COBRA database 111, 114, 123
  - community-selective scaffolds 69
  - computed molecular properties 107
  - computer encoded chemical reaction 94
  - consensus shapes
    - and center molecules, calculations 187, 188
    - to probe CCR5 extracellular pocket 190-192
  - COX-2 inhibitor 4
  - CP-99994
    - benzyl amino group 265
    - binding mode of 265
  - Cresset's field technology 270
  - cumulative scaffold frequency plots (CSFP) 49
  - cyan sticks 216
  - cycle graph 149
  - cyclin-dependent kinase (CDK) family 242
  - cyclooxygenase-2 (COX-2) 235
- d**
- data visualization 55
  - Daylight fingerprints (DFPs) 108, 110, 138, 139, 142
  - diarylthiazolotriazole 4
  - dictionary-based approach 108
  - 2,5-dioxopiperazine 267
  - DOGS program 94
  - DrugBank 43
  - drug discovery
    - application of Spark 206, 207
    - automatic devices 99
    - and design 3
    - Drug Guru 36
    - similarity searching in 155-157
  - Drug Guru program 36, 89, 90, 99
  - drug metabolism and pharmacokinetic (DMPK) 247
  - 3D scaffold replacement method 175
    - BROOD 179, 180
    - ChEMBLstructures 177
    - commercial structure 177
    - CSD structures 176
    - databasess 176, 177
    - filtering 177, 178
    - fragment generation 177, 178
    - fragment replacement search 178
    - molecule databases 175
    - ReCore 179
    - scoring 178
  - SHOP, as novel replacement scaffolds 178, 179
  - virtual structures 177
  - workflow 175, 176
  - 2D structure 98
- e**
- ECFP4 fingerprints 111, 114
  - electronic laboratory notebooks (ELNs) 95
  - enantiospecific inhibition 252
  - endothelial nitric oxide synthase (eNOS)-derived NO 283
  - ER activity, designed compounds with 236
  - ester linkage, in tryptophan-derived NK<sub>1</sub> antagonists 269
  - estrogen receptor (ER) 241
    - affinity 235
    - site point constraints 240
  - ethylenediamine fragment 286, 288
  - Extended Connectivity Record (ECTR), programs 16
  - eXtended electron distribution (XED) force field. *see* XED force field
- f**
- feature point pharmacophores (FEPOPS) 157-159
    - active recall, and scaffold hopping descriptor assessment 166
    - alignment of protein kinase C inhibitor 165
    - alternative alignment 168-170
    - atomic properties tocentroids, assignment of 161
    - average similarity of probes 168
    - chemical space uniqueness 171, 172
    - computation 159-162
    - defining scaffold hopping 163, 164
    - descriptor 160
    - generation of feature point pharmacophores 161
    - *k*-means and *k*-medoids calculations 160, 162
    - clustering 158
    - multiscale reduction of ATP atoms 159
    - multiple flexible conformers 160
    - Omega software, use of 162
    - perspective 172, 173
    - recovery of validated HTS actives, clusters, scaffolds, and ring systems 167
    - scaling and correlations 162
    - *in silico* target prediction 170, 171
    - in similarity searching and scaffold hopping 164-168

- feature trees 149
  - applications 152, 153
  - CoLibri software, use of 153
  - comparison 150
  - FTrees–FS system
  - exploration of combinatorial chemistry spaces 152, 153
  - using variant of Feature Trees representation 153
  - FTreesXL 152
  - generation 149, 150
  - implementations 152
  - MTree 152
  - RECAP fragmentation scheme 152, 153
  - retrospective validation 151, 152
- FEPOPS. *see* feature point pharmacophores (FEPOPS)
- FieldStere 270
- fingerprints 108. *See also* molecular interaction fingerprints
  - based virtual screening 109, 112
  - for ligands and proteins (FLAP) method 217
  - scenarios 224
- fragment-based drug design (FBDD) 238
- fragment connectivity rules 238
- fragment hopping
  - to design novel inhibitors, for neuronal nitric oxide synthase 283–288
  - minimal pharmacophoric elements and 281–283
  - nNOS inhibitors 287
  - to optimize neuronal nitric oxide synthase inhibitors 288, 289
  - schematic flow diagram 282
- freedom-to-operate (FTO) inquiry 17
- Free–Wilson analysis 17
- functional *vs.* structural molecular scaffolds 7
  
- g**
- Gaussian function 224
- GENSAL language 16
- Glu193 265
- glycine transporter type 1 (GlyT1) inhibitors 247
- G protein-coupled receptor (GPCR) 64, 280
  - ligand 220
- graphical user interface plugin 231
- graph matching 143, 144
- graph reduction
  - attempts to simplify objects 131
  - generation 133
  - extended reduced graph (ErG) approach 136, 137
  - node labeling 134, 135
  - reduction scheme 133, 134
  - Sheffield implementations 135, 136
- GRID, computational methods
  - based similarity searches 178
  - understanding selectivity of inhibitors for 281
- GTPcS functional assay 236
  
- h**
- halogen-substituted phenyl groups, usages. *see* fragment hopping
- H-bond acceptor 217
- heteroatoms 107
- hierarchical scaffolds 63
- high concentration screening (HCS) 279
- high-throughput screening (HTS) 9, 155, 166, 168, 279
  - applications 279
  - Merck’s effort 253
  - T-type Ca<sup>2+</sup> inhibitors 249
  - VU/MLCPN, chemical optimization 250
- His 265
  - Ala-replacement 265
  - significance 265
- HTS. *see* high-throughput screening (HTS)
  
- i**
- IADE software 89
- intellectual property (IP) space 247
- interaction annotated structural features (IASF) method 216
- inverse QSAR technique 89, 90
  
- k**
- Kohonen networks 54
  
- l**
- L-732138 266, 269
- L-737488, analog 269
- ligand-annotated target fingerprints 218, 222
- ligand-based hypothesis 155
- ligand–water–protein interactions 241
- lipophilicity 3, 88
- L-N<sup>ω</sup>-nitroarginine methyl ester (L-NAME) 290
- L-732138, template molecule 270
- Lys194 265
  
- m**
- Markush, Eugene 15
- Markush Input Language (MIL) 18
- Markush structure 15, 16

- correspondence between MIL file and 21, 22
  - economic importance 16
  - encoding 18
  - exact R groups 19
  - fused R groups 19, 20
  - inexact R groups 19
  - r\_group records 19
  - Menguin program 20, 21
  - MARPAT systems 17
  - maximum common substructure (MCS)
    - 9–11, 44, 84, 91
  - algorithms, challenges 9
  - MDDR database 109
    - activity classes from 109
    - scaffold-hopping searches 110
  - MDDR data set 139, 142
  - MDL fingerprint 108, 110, 111
  - medicinal chemistry scaffolds, enumerated
    - possibilities 47
    - integer descriptors 46
    - Lipkus' topology analysis 47
    - nonredundant library, in CAS registry 46
    - ring systems 46, 47
    - topologies of voids 46, 47
    - VEHICLE database 47
  - MEGx database 114
  - Menguin program 18
  - Merged Markush Service (MMS) 16, 17
  - MFP2 fingerprint 112
  - MIL file 18
  - molecular cloning studies 248
  - molecular geometry 107
  - molecular interaction fingerprints
    - ligand-annotated target 217–219
    - protein–ligand complexes
    - three-dimensional (3D) structures of 215
    - protein–ligand pharmacophores 217
    - target-annotated ligand 215, 216
    - interacting atom/fragment 216, 217
    - true target–ligand 220
    - association of 220–222
    - interaction pattern 222–225
  - molecular libraries production center network (MLPCN) 248
  - molecular libraries screening center network (MLSCN) 248
  - molecular topology 107
  - molecular weight 84–86, 88, 107, 261, 279
  - molecule-based approach 108
  - Molecule Evaluator 89
  - MotifScore 223
  - multiple objective optimization 90
  - multiple solvent crystal structure (MSCS)
    - method 281
  - Murcko scaffold 110
  - MUV data set 111
- n**
- natural products, source of novel scaffolds 45, 46
  - NATx database 114
  - neurokinin 1 (NK<sub>1</sub>) receptor 260
    - antagonists 262
    - residues, involved in binding of nonpeptide antagonists 265
  - neuronal nitric oxide synthase (nNOS) 283
  - neuropeptide SP, NMR structure 265
  - neuropeptide substance 261
  - nitric oxide synthase (NOS), chemical structures 285
  - nitroarginine-containing dipeptide/peptidomimetic inhibitors 284
  - nNOS
    - binding conformation 289
    - crystal structure 288
    - dipeptide/peptidomimetic inhibitors 284
    - inhibitors, minimal pharmacophoric elements 286
  - N5SB polymerase 3
  - NVP-AUY922, HSP90 inhibitor 6
- o**
- objective and invariant scaffold representations 7
    - molecular frameworks 7, 8
    - scaffold tree 8
  - oxazolidinone 268
  - 2-oxopiperazine 267
- p**
- ParaFit program 188–190
  - ParaSurf program 188–190
  - PGVL system 97
  - pharmacological similarity 195
    - chemotype trap 195, 196
    - G protein-coupled receptors 195
    - ligand 195, 198
    - pattern 196–199
    - shape compatibility 195
    - van der Waals forces 195
  - pharmacophore-based interacting fingerprints 217
  - pi–cation interaction 219
  - Pipeline Pilot software 110
  - piperazine ring system 268

- polarity 3
  - polar surface area (PSA) 107, 286
  - potency-based scaffold discontinuity score (PScS) 71
  - privileged scaffolds 11
  - privileged substructures 63
  - Pro271 265
  - programmable compounds 99
  - promiscuous chemotypes 68
  - promiscuous scaffolds, in drugs 70, 71
  - protein and ligand fingerprints (PLFPs) 221
  - protein–ligand association fingerprint 220
  - protein ligand interaction explorer (PROLIX) 223
  - protein–ligand interaction fingerprints 218
  - protein–ligand interaction
    - pharmacophores 217
  - protein–ligand structural alignments 222
  - pseudo-SMILES encoding 138
  - PubChem 32, 33, 43, 62, 86
  - Putative ligand structures 232
  - PyMOL graphical user interface 232
  - pyrrolidine ring 286
- q**
- quantitative structure–activity relationship (QSAR) models 152
    - feature tree representations of molecules 152
    - Free–Wilson analysis 33
    - inverse 89, 90, 98
- r**
- rabbit kits
    - neurobehavioral assessment 290, 291
    - nitric oxide synthase/nitric oxide concentration 290
  - random virtual compounds 83
  - RDKit fingerprint 124
  - reaction SMARTS 93, 94
  - readily synthesizable compounds 94
    - construction 94, 95
    - iterative approaches 96
    - outside big pharma 96
    - searching 95
  - real-life reactions, for in silico molecule construction 93, 94
  - ReCore program 179
  - reduced graph (RG) 131, 133, 141
    - comparison and usage 137, 138
    - augmenting fingerprints, with edit distance 140, 141
    - bioisostere encoding 144
      - conventional fingerprinting 138, 139
      - dopaminergic activity retrieved 138
      - extended reduced graph fingerprints 141–143
      - graph matching approaches 143, 144
      - RG-specific fingerprints 139, 140
      - structural diversity of 5HT reuptake inhibitors 142
      - key challenges, to assess molecular similarity 145
  - reference structure 107
  - Reflex method 240
  - R/F reduction scheme 135
  - RG. *see* reduced graph (RG)
  - ring fragments 233
  - rotating spherical polar fourier expansions 185, 186
- s**
- SAR data 97
  - scaffold composition
    - drugs and small-molecule libraries 45, 46
    - to interpret bioactivity data 48
    - SCINS code 48
    - structure–activity relationships 48
      - medicinal chemistry libraries 46, 47
      - medicinal chemistry space 41–45
      - molecular framework analysis 45, 46
      - drug and drug-like library 46
      - natural product library 46
    - study based on MCS 44
  - scaffold definition 64, 65, 84
  - scaffold diversity
    - defining 41
    - in medicinal chemistry 39–41
    - medicinal chemistry space
      - metrics for quantifying 48–53
      - visualizing scaffold diversity 53–56
    - of pharmaceutical targets 76–78
    - structural relationships between scaffolds 76, 77
  - scaffold hopping 3, 31, 76, 78, 107, 240–242, 247–248
    - access novel calcium T-type channel inhibitors 250–253
    - access novel glycine transporter type 1 (GlyT1) inhibitors 253–254
    - application of 235
    - bioisostere 259
    - capability 110
    - from a CCR3 antagonist to existing library compound 173
    - into chiral 3-aminopiperidine cores 251

- into [3.1.0] cores 252
- *de novo* design 231
- Drug Guru program 36
- fast-follower project 36
- fragment-based drug design 279–281
- minimal pharmacophoric elements/  
fragment hopping 281–283
- neuronal nitric oxide synthase 283–288
- optimize neuronal nitric oxide synthase  
inhibitors 288–289
- Free–Wilson analysis 33–35
- neurokinin 1 receptor (NK<sub>1</sub>R) 260, 261
- target active site and binding mode 264,  
265
- neurokinin 1 receptor antagonists 261–264
- bioisosteric replacements 266–273
- neurokinin 1 (NK<sub>1</sub>) therapeutic areas 259,  
260
- neuronal nitric oxide synthase inhibitors,  
application of
- cerebral palsy prevention 289–291
- periscope system assisting 32
- potential 76
- CATS1 and CATS2 descriptors 125
- descriptors, actives-retrieving performance  
categories 124, 125
- determining 125
- heatmap depicting *p*-values 124
- retrospective evaluation of enrichment  
and 122–126
- ROC-related BEDROC score 123
- virtual screening benchmark 123
- predictive studies, using 2D  
fingerprints 112–114
- prospective applications 126–128
- substructure searching 32, 33
- T-type calcium channel inhibitors 248–250
- using 2D fingerprints, retrospective  
studies 109–112
- in virtual screening 78
- scaffold network graphs, of drugs 56
- scaffold representations
- history 4–7
- of kinase inhibitor lapatinib 40
- libraries A and B 42
- scaffold space, visualizations 96, 97
- scaffolds, with defined activity progression 73
- activity profile sequences 73–75
- conserved scaffolds 75
- scaffold-target family profiles 70
- scaling bit positions 217
- SCINS (scaffold identification and naming  
systems) 48, 52, 163, 164
- descriptor 163, 172
- ScreenScore 234
- search algorithm 22–25
- i3am search algorithm 23
- matching R groups 25
- exact R groups 25–27
- fused R groups 28
- hydrogen atoms 29, 30
- inexact R Groups 27, 28
- managing multiple fragment/R group  
matches 30, 31
- molecules matched against Markush 24, 25
- indole core 24
- match C<sub>1–6</sub> alkoxy 25
- methoxycarbonyl and chloride groups 25
- R groups and portions of molecule  
unmatched 24
- total score 25
- Xenon atoms 24
- selectivity, of scaffolds 63
- privileged substructures 63, 64
- target community-selective scaffolds 64–66
- target-selective scaffolds 67
- self-organizing maps (SOMs) 54, 126, 281
- Shannon entropy 51
- shell residue fingerprint (SRFP) 223
- SHOP program 178, 179
- similarity searching, in drug discovery  
155–157
- 4D chemical similarity method (*see* feature  
point pharmacophores (FEPOPS))
- 2D similarity methods 156, 157
- graph-like representations, of  
compounds 156
- high throughput screening (HTS) 155
- ligand-based hypothesis 155
- Markush structures 156
- scaffold hopping 156
- structure–activity relationships 156
- Skelgen 231
- cyclin dependent kinase 2 (CDK2) 235
- cyclooxygenase-2 (COX-2) 235
- estrogen receptor 235, 236
- histamine H<sub>3</sub> inverse agonists 236
- principles 231
- PyMOL graphical user interface 232
- retrospective validation study 235
- scaffold hopping 240–242
- using fixed fragments 237, 238
- using site points 238–240
- structure generation/optimization
- fragments/fragment sets 232–233
- ligand-based design 234–235

- scoring 234
- validation studies 235
- Skelgen fragment 237
- SMIRKS 87, 89
- SOMs. *see* self-organizing maps (SOMs)
- Spark
  - in drug discovery scenarios, applications 206, 207
  - P38 kinase inhibitor fragment growing using 207–209
  - workung 202
  - selecting fragment replacement site 206
  - software 202, 205
- SparkV10 270, 271, 272
  - heterocyclic bioisosteres of the ester linkage 273
  - template molecule L-732138 271
- spherical harmonic surface
  - shape similarity 186, 187
- spherical harmonic surfaces 183–185
- stearoyl-CoA desaturase inhibitor 3
- steric interactions 272, 285
- structural interaction fingerprint (SIFt) 218
- structure–activity relationships (SARs) 61, 84
- structure-based de novo design 90–92
- substance P receptor (SPR). *see* neurokinin 1 receptor
- substrate activity screening (SAS) 279
- Surflex-Dock score 225
- SVM model 221
- SYNOPSIS tool 93

## t

- tachykinin NK<sub>1</sub> family 264
- tachykinin receptor 1 (TACR1). *see* neurokinin 1 receptor
- Tanimoto coefficient 107, 108
  - values 78
- tan ribbons 216
- target-annotated ligand fingerprints 216
- target community-selective scaffolds 64–66
- target–ligand fingerprints 220
- target promiscuity of scaffolds 67
  - promiscuous BM scaffolds and CSKs 67–70
  - promiscuous scaffolds in drugs 70, 71
  - scaffold–target family profiles 70
- target selectivity (TS) value 67
- thiophene S-oxide 4
- TIFP fingerprint 224
- topological structure, autocorrelation 119
- toxicity 3
- tree maps 54
- Tripos Unity fingerprint 110

- tryptophan-derived NK<sub>1</sub> receptor
  - antagonists 266, 270
  - binding affinity 273
  - ester linkages, case study 266, 273
  - heterocyclic bioisosteres 267
- T-type Ca<sup>2+</sup> inhibitors
  - high-throughput screen (HTS) 249
  - Merck piperidine series 251
  - second-generation 249
- T-type calcium channel family 248
- Tversky coefficient 108

## u

- Unity fingerprint 108

## v

- valid molecular fields, generation of 199. *See also* pharmacological similarity
  - ACC approximation 199
  - Coulombic interactions 199
  - MM force 199
  - molecular mechanics 199
  - validating position and pattern of field points, tools for 200
  - Cambridge Crystallographic Database 200
  - XED model 199
- Vanderbilt GlyT1 inhibitors 254
- vBROOD system 180
- virtual chemistry 83
- virtual compounds, iterative generation 88
  - analog generators 89
  - chemical modifications, manual selection of 88, 89
  - creation, different ways to 92
  - inverse QSAR 89, 90
  - multiple objective optimization 90
  - structure-based de novo design 90–92
  - transformations 88
- virtual libraries 88, 92
  - perspectives 98
- virtual synthesis 92
  - construction 94, 95
  - iterative approaches 96
  - outside big pharma 96
  - readily synthesizable compounds 94
  - real-life reactions 93
  - searching 95
  - synthetic tractability 92, 93
- visualizations, of scaffold space 96, 97

## w

- WOMBAT database 144
- World Drug Alerts 242

**x**

- XED force field 195, 200–202
  - applications 200
  - applied to scaffold hopping in Spark 202
  - to benzene 203
  - constructs
    - polarizable, and allowing for nuclear charge 201
    - types 200, 201
  - creating new molecules 208–210
  - desymmetrization of the ether oxygen atoms by 203
  - electrons distribution 200

- far-reaching consequences of using molecular fields
  - as measures of similarity 212, 213
  - improvement in electrostatic behavior 202, 204
  - model reflecting intuitive molecular properties 199
  - new potential inhibitors 209–212
  - XED MM method 200
- X-ray crystallography 279

**z**

- ZINC database 111, 152